Dashboard
Manage Tickers

ETNB


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-89bio-maintains-29-price-target
Cantor Fitzgerald Reiterates Overweight on...
07/01/2024 15:05:58

Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.

cantor-fitzgerald-reiterates-overweight-on-89bio-maintains-29-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/17/2024 17:29:54

Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.

cantor-fitzgerald-reiterates-overweight-on-89bio-maintains-29-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/12/2024 16:14:15

Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.

hc-wainwright--co-reiterates-buy-on-89bio-maintains-29-price-target
HC Wainwright & Co. Reiterates Buy on 89bi...
06/11/2024 10:42:58

HC Wainwright & Co. analyst Ed Arce reiterates 89bio (NASDAQ:ETNB) with a Buy and maintains $29 price target.

whats-going-on-with-fattly-liver-disease-focused-madrigal-pharmaceuticals-sagimet-biosciences-shares-on-wednesday
What's Going On With Fattly Liver Disease ...
06/05/2024 19:17:50

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress ...

89bio-will-present-48-week-data-from-enliven-phase-2b-pegozafermin-trial-in-mash-at-easl-international-liver-congress
89bio Will Present 48-Week Data From ENLIV...
05/22/2024 20:22:47

89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innov...

cantor-fitzgerald-reiterates-overweight-on-89bio-maintains-29-price-target
Cantor Fitzgerald Reiterates Overweight on...
05/17/2024 13:49:16

Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.

hc-wainwright--co-reiterates-buy-on-89bio-maintains-29-price-target
HC Wainwright & Co. Reiterates Buy on 89bi...
05/17/2024 12:13:50

HC Wainwright & Co. analyst Ed Arce reiterates 89bio (NASDAQ:ETNB) with a Buy and maintains $29 price target.

hc-wainwright--co-reiterates-buy-on-89bio-maintains-29-price-target
HC Wainwright & Co. Reiterates Buy on 89bi...
05/16/2024 10:56:31

HC Wainwright & Co. analyst Ed Arce reiterates 89bio (NASDAQ:ETNB) with a Buy and maintains $29 price target.

evercore-isi-group-maintains-outperform-on-89bio-lowers-price-target-to-33
Evercore ISI Group Maintains Outperform on...
05/15/2024 13:19:59

Evercore ISI Group analyst Liisa Bayko maintains 89bio (NASDAQ:ETNB) with a Outperform and lowers the price target from $37 ...

89bio-initiates-phase-3-enlighten-cirrhosis-trial-of-pegozafermin-in-mash-patients-with-compensated-cirrhosis
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosi...
05/14/2024 12:08:43

hc-wainwright--co-maintains-buy-on-89bio-lowers-price-target-to-29
HC Wainwright & Co. Maintains Buy on 89bio...
05/10/2024 12:09:58

HC Wainwright & Co. analyst Ed Arce maintains 89bio (NASDAQ:ETNB) with a Buy and lowers the price target from $31 to $29.

89bio-q1-2024-gaap-eps-054-misses-046-estimate
89bio Q1 2024 GAAP EPS $(0.54) Misses $(0....
05/09/2024 21:28:46

89bio (NASDAQ:ETNB) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.46) by 17...

b-of-a-securities-assumes-89bio-at-buy-announces-price-target-of-30
B of A Securities Assumes 89bio at Buy, An...
04/22/2024 10:14:26

B of A Securities analyst Alexandria Hammond assumes 89bio (NASDAQ:ETNB) with a Buy rating and announces Price Target of $30.

on-april-4-2024-89bio-entered-into-collaboration-agreement-with-bibo-biopharma-engineering---filing
On April 4, 2024, 89Bio Entered Into Colla...
04/10/2024 20:35:46

BiBo will construct a production facility specifically designed to supply the Company with pegozafermin for commercialization, ...

cantor-fitzgerald-reiterates-overweight-on-89bio-maintains-29-price-target
Cantor Fitzgerald Reiterates Overweight on...
04/05/2024 13:23:32

Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.

hc-wainwright--co-maintains-buy-on-89bio-maintains-31-price-target
HC Wainwright & Co. Maintains Buy on 89bio...
03/27/2024 17:53:03

HC Wainwright & Co. analyst Ed Arce maintains 89bio (NASDAQ:ETNB) with a Buy and maintains $31 price target.

89bio-receives-ema-prime-status-for-pegozafermin-in-the-treatment-of-metabolic-dysfunction-associated-steatohepatitis-with-fibrosis-and-compensated-cirrhosis
89bio Receives EMA PRIME Status For Pegoza...
03/27/2024 12:16:06

–PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin– –Phase 3 ENLIGHTEN-Fibrosis trial ...

hc-wainwright--co-maintains-buy-on-89bio-maintains-31-price-target
HC Wainwright & Co. Maintains Buy on 89bio...
03/13/2024 13:50:31

HC Wainwright & Co. analyst Ed Arce maintains 89bio (NASDAQ:ETNB) with a Buy and maintains $31 price target.

89bio-initiates-phase-3-enlighten-fibrosis-trial-of-pegozafermin-in-non-cirrhotic-metabolic-dysfunction-associated-steatohepatitis-patients-with-fibrosis
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis...
03/12/2024 12:02:25

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)